For future studies, it would be interesting to investigate more novel drugs, such as the monoclonal antibody pertuzumab and the antibody-drug conjugates T-DM1 and/or trastuzumab deruxtecan, which recently has been approved as standard treatment for early and advanced HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.